Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 26.01 CNY, compared to the current stock price of 20.87 CNY [7]. Core Views - The company's performance in Q1 2025 showed a decline in operating income by 3.58% year-on-year, with a decrease in pre-provision profit by 4.35% and net profit attributable to shareholders down by 2.22%. The main factors affecting performance were the expansion of interest-earning assets and a decline in net non-interest income [2][10]. - The asset quality remains stable, with a non-performing loan ratio of 1.08% and a provision coverage ratio of 233.42% as of Q1 2025, indicating a reasonable level of asset quality management [10][11]. Summary by Sections Financial Performance - In Q1 2025, the company's total assets grew by 3.65% year-on-year, with total loans increasing by 4.83%. The bank added 123.4 billion CNY in total assets and 78.8 billion CNY in loans during the quarter [3][4]. - The net interest margin for Q1 2025 was 1.80%, showing a year-on-year decline of 7 basis points, while the cost of liabilities decreased, helping to mitigate the impact of declining interest margins [6][10]. Loan and Deposit Structure - Corporate loans showed a year-on-year growth of 6.33%, with a focus on supporting the real economy, particularly in green and technology loans, which exceeded 1 trillion CNY [4][5]. - Retail loan growth was weak, with a year-on-year increase of only 0.96%, and a net decrease of 26 billion CNY in retail loans during the quarter [4]. Non-Interest Income and Cost Management - Non-interest income declined by 12.42% year-on-year, primarily due to a 21.50% drop in investment income, although net fee income increased by 8.54% [10][11]. - The cost-to-income ratio increased slightly to 24.13%, reflecting the impact of declining income [11]. Future Outlook - The company is expected to maintain stable credit issuance while enhancing deposit cost control, with an anticipated decline in net interest margin of around 10 basis points for the year [11]. - Revenue is projected to grow by 0.54% year-on-year in 2025, with net profit growth estimated at 1.91% [11].

Group 1: Economic Indicators - April PMI for manufacturing dropped to 49, a decrease of 1.5 percentage points, marking the first contraction since the "926" policy[4] - April non-farm payrolls in the U.S. increased by 177,000, a significant drop of 51,000 from the previous month[14] - Q1 2025 GDP growth rate was -0.3%, a decline of 2.7 percentage points from Q4 2024, the lowest in nearly four years[10] Group 2: Consumer Behavior - During the May Day holiday, cross-regional mobility reached 33.27 million people, a year-on-year increase of 6.2%[7] - Consumer spending is recovering steadily, with travel and tourism showing significant growth, particularly in scenic areas where visitor numbers increased by around 20%[7] - The correlation between consumer spending and the "old-for-new" policy is low, indicating a rise in spontaneous consumption tendencies[9] Group 3: Trade and Tariff Impact - The U.S. tariff policy has led to a noticeable decline in exports, with new export orders and backlogs decreasing significantly[4] - The cancellation of the tariff exemption for goods valued at $800 will significantly impact small businesses and cross-border e-commerce[5] - The increase in import rates due to tariff policies has contributed to a surge in inventory levels, negatively affecting economic performance[12]

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 55 CNY, maintaining the rating [4][13]. Core Views - The company's Q1 2025 performance shows a reliance on scale expansion for growth, with a year-on-year revenue decline of 3.09% and a net profit increase of 2.08% [1][12]. - The bank's strong deposit base supports asset expansion, despite a narrowing net interest margin and slowing non-interest income growth [1][12]. - The outlook for 2025 suggests a modest revenue growth of 0.61% and a net profit growth of 1.24%, with expectations of a recovery in the capital market aiding performance [13]. Summary by Sections Financial Performance - In Q1 2025, the bank's average interest-earning assets increased by 8.7% year-on-year, with new interest-earning assets amounting to 176.6 billion CNY, a year-on-year increase of 8.4 billion CNY [1][18]. - The net interest margin for Q1 2025 was 1.91%, down 11 basis points year-on-year, primarily due to a decrease in asset yield [2][3]. Loan and Deposit Structure - New loans in Q1 were primarily driven by corporate lending, while retail lending showed weakness, particularly in credit card loans [2][12]. - The bank's interest-bearing liabilities grew by 8.6% year-on-year, with deposits increasing by 9.4%, significantly outpacing loan growth of 5.2% [2][12]. Non-Interest Income - Non-interest income from fees and commissions decreased by 2.51% year-on-year, with wealth management income growing by 10.45% [8][12]. - Other non-interest income faced pressure, declining by 22.2% year-on-year due to market rate fluctuations affecting bond and fund investments [9][12]. Asset Quality - The bank's non-performing loan ratio remained stable at 0.94%, with a slight increase in the attention ratio to 1.36% [9][10]. - The bank's provision coverage ratio is stable at around 410%, indicating strong risk absorption capacity [10][12]. Future Outlook - The bank is expected to face continued pressure on net interest margins due to weak effective financing demand, but its strong deposit advantage is anticipated to maintain a relatively high margin compared to peers [8][12]. - The report highlights the potential for recovery in non-interest income as market conditions improve, particularly in the capital markets [9][12].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the pharmaceutical sector [4] Core Insights - The pharmaceutical industry has shown significant performance differentiation, with innovation leading to long-term growth despite overall revenue declines in 2024 and Q1 2025 [1][17] - The overall revenue for the pharmaceutical sector in 2024 decreased by 1.73% year-on-year, with net profit attributable to shareholders declining by 14.06% [1][19] - In Q1 2025, the sector's revenue further declined by 4.34%, and net profit decreased by 8.87% [1][19] - The valuation of the pharmaceutical sector has seen a notable increase since September 2024, with the PE ratio stabilizing around 30 times, although still considered low historically [1][38] Summary by Sections 1. Overall Industry Situation - The pharmaceutical sector's overall performance has been analyzed through a systematic optimization of company classifications, excluding companies with non-core pharmaceutical operations [17] - The revenue and profit trends indicate a challenging environment, with a focus on innovation as a key driver for future growth [1][17] 2. Performance of Sub-sectors 2.1. Chemical Preparations - In 2024, the chemical preparations sector's revenue grew by 1.97%, while net profit decreased slightly by 0.24% [2] - Q1 2025 saw a revenue decline of 1.83%, but net profit increased by 3.14%, indicating a gradual recovery [2] 2.2. Chemical Raw Materials - The chemical raw materials sector experienced a revenue increase of 0.90% in 2024, with net profit soaring by 133.78% [2] - In Q1 2025, net profit continued to grow by 6.81%, reflecting stable pricing for certain raw materials [2] 2.3. Biological Products - The biological products sector faced significant challenges, with a revenue decline of 28.01% in 2024 and a further drop of 34.48% in Q1 2025 [3] 2.4. Medical Services - The medical services sector's revenue grew by 0.46% in 2024, but net profit fell by 27.82% [9] - Q1 2025 showed a revenue decline of 1.27%, yet net profit increased by 10.71%, indicating signs of recovery [9] 2.5. Medical Devices - The medical devices sector's revenue grew by 0.64% in 2024, but net profit decreased by 8.47% [10] - In Q1 2025, revenue declined by 6.71%, with net profit down by 15.14%, reflecting ongoing pressures [10] 2.6. Pharmaceutical Commerce - The pharmaceutical commerce sector's revenue grew by 0.63% in 2024, but net profit fell by 15.60% [11] - Q1 2025 saw a slight revenue decline of 0.90% and a net profit decrease of 2.59% [11] 2.7. Traditional Chinese Medicine - The traditional Chinese medicine sector's revenue decreased by 4.50% in 2024, with net profit down by 15.02% [11] - In Q1 2025, revenue further declined by 8.22%, but there are expectations for gradual recovery as inventory issues are resolved [11] 3. Fund Holdings - As of Q1 2025, the proportion of public funds holding pharmaceutical stocks increased to 9.05%, up by 0.47 percentage points [1][45] - The pharmaceutical sector accounted for 6.25% of the total market capitalization of A-shares, reflecting a slight increase [1][45]

Investment Rating - The investment rating for Chengdu Bank is "Accumulate-A" with a 6-month target price of 18.87 CNY, compared to the current stock price of 16.98 CNY [4]. Core Views - Chengdu Bank has demonstrated robust growth in both revenue and profit, with a revenue growth rate of 5.89% for 2024 and a net profit growth rate of 10.17% for the same year. For Q1 2025, the revenue increased by 3.17% year-on-year, and net profit grew by 5.64% [1][9]. - The bank's performance is primarily driven by the expansion of interest-earning assets, although net interest margin compression has been a significant drag on growth [1][8]. - The bank's asset quality remains strong, with a non-performing loan ratio of 0.66% and a provision coverage ratio of 456% as of Q1 2025 [9][21]. Summary by Sections Financial Performance - Chengdu Bank's total assets grew by 14.56% year-on-year to reach a total of 285 billion CNY by the end of 2024, with a significant increase in loans by 18.76% [1][2]. - For Q1 2025, total assets increased by 13.25% year-on-year, with loans contributing significantly to this growth [1][2]. Loan Growth - Corporate loans showed steady growth, with balances increasing by 20.31% year-on-year by the end of 2024 and 17.69% by the end of Q1 2025 [2]. - Retail loans also performed well, with a year-on-year growth of 12.46% by the end of 2024 and 13.37% by the end of Q1 2025 [3]. Deposit Growth - Total deposits increased by 13.20% year-on-year by the end of 2024 and 15.40% by the end of Q1 2025, with retail deposits showing a significant rise [3][7]. Non-Interest Income - Non-interest income grew by 24.11% year-on-year in Q4 2024, primarily driven by investment income, while fee income saw a decline [9][21]. Asset Quality - The bank maintained a low non-performing loan ratio of 0.66% and a strong provision coverage ratio, indicating solid risk management [9][21]. Future Outlook - Chengdu Bank is expected to achieve a revenue growth of 8.17% and a profit growth of 9.25% in 2025, supported by its strong asset quality and robust loan growth strategy [9][10].

Investment Rating - The investment rating for Postal Savings Bank is "Buy-A" with a target price of 6.31 CNY over the next six months [5]. Core Views - The report highlights that the bank's revenue decreased by 0.07% year-on-year in Q1 2025, while pre-provision profit grew by 6.20%. However, net profit attributable to shareholders fell by 2.62% year-on-year [1]. - The growth in profit is primarily supported by the expansion of interest-earning assets and cost reduction, although narrowing net interest margins and increased provisioning have negatively impacted performance [1][11]. Summary by Sections Financial Performance - As of the end of Q1 2025, total assets of Postal Savings Bank increased by 8.31% year-on-year, with total loans growing by 9.78% and financial investments by 9.45% [1]. - The bank's net interest margin for Q1 2025 was measured at 1.71%, showing a decline of 21 basis points year-on-year [4][22]. - Non-interest income increased by 14.83% year-on-year, with net fees growing by 8.76% and other non-interest income rising by 21.70% [10]. Loan and Deposit Growth - Corporate loans saw a significant increase of 15.17% year-on-year, with a quarterly addition of 362 billion CNY [2]. - Retail loans grew by 4.27% year-on-year, with a quarterly increase of 678 billion CNY [2]. - Total deposits rose by 9.22% year-on-year, with corporate and retail deposits increasing by 20.46% and 7.94%, respectively [3]. Asset Quality and Provisions - The non-performing loan ratio stood at 0.91% at the end of Q1 2025, remaining stable [10]. - The bank increased its provisioning efforts, with a coverage ratio of 266.13% [10]. Future Outlook - The bank plans to enhance support for key sectors such as new productivity and inclusive small and micro enterprises, while also increasing consumer loan offerings [11]. - Revenue growth is projected at 1.43% for 2025, with net profit growth expected at 2.65% [11].

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 105.17 CNY, maintaining the rating [5]. Core Views - The company has demonstrated strong performance in its financial results, with a revenue of 2.548 billion CNY in 2024, representing a year-on-year growth of 32.63%. The net profit attributable to shareholders reached 683 million CNY, up 67.64% year-on-year [1]. - The company is actively advancing its independent brand strategy, with significant progress in the overseas market, particularly in the United States, where the "MOTOGallery" project has established over 500 store-in-store locations across 32 states [2]. - The company has successfully expanded its customer base, adding 96 new retail customers in 2024, all of which are U.S. retailers, enhancing its customer structure and channel resources [3]. Financial Performance - In 2024, the company's revenue from electric sofas was 1.955 billion CNY, a year-on-year increase of 37.13%, while electric beds generated 346 million CNY, up 20.45% [2]. - The gross profit margin for 2024 was 39.35%, an increase of 5.40 percentage points year-on-year, while the net profit margin was 26.80%, up 5.60 percentage points [11]. - The company plans to distribute a cash dividend of 5.0 CNY for every 10 shares and to increase capital by converting reserves into shares at a ratio of 3 shares for every 10 shares held [1]. Customer and Market Expansion - The company has seen a significant increase in procurement amounts from its top 10 customers, with nine out of ten reporting growth, and three customers exceeding 100% growth [3]. - As of Q1 2025, the company’s retail customers in the U.S. accounted for 88.19% of its total U.S. furniture customers, with sales to U.S. retailers contributing 64.75% of total revenue [10]. - The company’s retail channel layout in the U.S. has shown significant effectiveness, with a focus on large retailers driving steady growth [10]. Future Projections - The company is expected to achieve revenues of 3.162 billion CNY, 3.850 billion CNY, and 4.631 billion CNY for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 24.10%, 21.73%, and 20.29% [15]. - The projected net profits for the same years are 794 million CNY, 931 million CNY, and 1.107 billion CNY, with growth rates of 16.25%, 17.25%, and 18.90% [15].

Investment Rating - The investment rating for the company is "Buy-A" with a six-month target price of 69.82 CNY [4][7]. Core Views - The company has shown consistent revenue growth, achieving 1.768 billion CNY in 2024, a 41.37% increase from 2023, and maintaining a global market share among the top three in conductive silicon carbide substrates [2][3]. - The company is increasing its R&D investment in large-size products, with R&D expenses rising to 0.45 billion CNY in Q1 2025 from 0.22 billion CNY in the same period last year [2]. - The demand for silicon carbide is expected to grow significantly due to its applications in AI data centers and emerging markets like AI glasses, with projections indicating a market size exceeding 800 billion CNY in AI data centers by 2030 [3]. Financial Summary - The company reported a revenue of 4.08 billion CNY in Q1 2025, a decrease of 4.25% year-on-year, and a net profit of 0.09 billion CNY, down 81.52% year-on-year [1]. - Forecasted revenues for 2025, 2026, and 2027 are 2.502 billion CNY, 3.217 billion CNY, and 4.118 billion CNY respectively, with net profits expected to be 0.271 billion CNY, 0.415 billion CNY, and 0.549 billion CNY [4][8]. - The company’s market capitalization is approximately 24.96 billion CNY, with a circulating market value of about 17.45 billion CNY [4].

Investment Rating - The report assigns a "Buy-A" investment rating to the company, with a target price of HKD 45.45 for the next six months [4][6][18]. Core Insights - The company achieved a revenue of CNY 4.052 billion in 2024, representing a year-on-year growth of 90.80%, and a net profit attributable to shareholders of CNY 1.070 billion, up 277.24% year-on-year [2][4]. - The growth is attributed to the continuous increase in ADC project numbers, the steady advancement of group projects to later stages, and improvements in operational efficiency [2][3]. - The company signed 53 new comprehensive projects in 2024, with an unfulfilled order amounting to USD 991 million, reflecting a 71% increase [3]. Revenue and Profit Forecast - The company is projected to achieve revenues of CNY 5.589 billion, CNY 7.433 billion, and CNY 9.515 billion for the years 2025 to 2027, with year-on-year growth rates of 37.93%, 32.98%, and 28.02% respectively [12][20]. - The net profit attributable to shareholders is expected to be CNY 1.371 billion, CNY 1.696 billion, and CNY 2.076 billion for the same years, with growth rates of 28.09%, 23.76%, and 22.41% respectively [12][20]. Valuation Analysis - The report indicates that the company's current price-to-earnings (PE) ratio is 29.76, which is close to its historical average [14][18]. - The estimated earnings per share (EPS) for 2025 is projected to be CNY 1.14, corresponding to a PE of 37 times [4][18]. - The report highlights that the company is well-positioned to benefit from the growing demand for ADC drug development and the high outsourcing rate in the industry [17].

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 42.88 CNY, compared to the current stock price of 36.50 CNY [4]. Core Insights - The company achieved a revenue of 2.513 billion CNY in 2024, marking a year-on-year growth of 33.13%, and recorded a net profit of 112 million CNY, indicating its first profitable year since listing [1][11]. - The core product, the recombinant factor VIII product Anjain®, saw stable sales with a revenue of 1.89 billion CNY in 2024, reflecting a growth of 6.18% despite price pressures from regional procurement [3][9]. - The company is actively expanding its overseas market presence, having signed agreements with partners in over ten "Belt and Road" countries and obtaining regulatory approvals for product launches in Pakistan and Indonesia [3][9]. Financial Performance - In Q1 2025, the company reported a revenue of 520 million CNY, a decrease of 15.15% year-on-year, with a net profit of 64 million CNY, down 14.06% [1]. - The gross margin for 2024 was 95.91%, a slight decline of 1.20 percentage points, while the gross margin for the core product Anjain® was 96.89% [2]. - The company’s R&D expenses in 2024 were 911 million CNY, a decrease of 20.64%, primarily due to most products being in early clinical research stages [2][10]. Market Strategy - The company has implemented flexible market strategies to ensure compliance with procurement pricing and to expand market share for Anjain® [3]. - The sales of antibody drugs, including Anpingxi® and two biosimilars, exceeded 620 million CNY in 2024, showing a significant growth of 499.80% [9]. - The company is focusing on real-world studies to gather clinical data, enhancing treatment protocols and patient confidence [9]. Future Projections - Revenue growth is projected at 16.9%, 20.8%, and 16.4% for 2025 to 2027, with net profit growth expected at 86.1%, 114.0%, and 62.6% respectively [11][12].